To assess prospectively, the response of moderate to severe atopic eczema to a standard course of narrowband ultraviolet B phototherapy by using validated objective and subjective scoring systems.
Children with moderate to severe atopic eczema prescribed a course of narrowband UVB phototherapy were scored (using validated scoring systems) objectively and subjectively before, during and after the course of treatment, as well as 3 and 6 months post treatment (to determine length of remission). Their scores were compared to a control group. The control group comprised children with moderate to severe atopic eczema who were offered UVB but were unable to undertake the treatment.
Study Type
OBSERVATIONAL
Enrollment
58
Twice weekly exposures for a total of 24 exposures using a standard phototherapy protocol.
Royal Victoria Infirmary
Newcastle upon Tyne, United Kingdom
Score at the end of treatment compared to the control group
Measurement of Six Area Six Sign Atopic Dermatitis (SASSAD) score and percentage surface area affected of those treated with narrowband UVB as compared to a control group
Time frame: 12 weeks
Subjective scores at the end of treatment as compared to controls
Subjective scoring using Patient Outcome Eczema Measure (POEM), Children's Dermatology Life Quality Index (CDLQI), Dermatitis Family Impact Questionnaire (DFI), Visual analogue scale (VAS) for itch and sleep loss
Time frame: 12 weeks
objective scores at 3 months post treatment compared to controls
Objective Six Area Six Sign Atopic Dermatitis (SASSAD) score and percentage surface area affected in the treated group at 3 months post treatment as compared to controls.
Time frame: 3 months
Association of filaggrin status with outcome
To determine if response to phototherapy is determined by the presence of a homozygous or compound heterozygous filaggrin mutation.
Time frame: 12 weeks
Subjective scores at 3 months post treatment compared to controls
Subjective scores (Patient Outcome Eczema Measure (POEM),Children's Dermatology Life Quality Index (CDLQI), Dermatitis Family Impact Questionnaire (DFI), Visual Analogue Scale (VAS) for itch and sleep loss) in the treated group at 3 months post treatment as compared to controls.
Time frame: 3 months
Subjective scores at 6 months post treatment compared to controls
Subjective scores (Patient Outcome Eczema Measure (POEM),Children's Dermatology Life Quality Index (CDLQI), Dermatitis Family Impact Questionnaire (DFI), Visual Analogue Scale (VAS) for itch and sleep loss) in the treated group at 6 months post treatment as compared to controls.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 6 months
Objective scores at 6 months post treatment compared to controls
Objective Six Area Six Sign Atopic Dermatitis (SASSAD) score and percentage surface area affected in the treated group at 6 months post treatment as compared to controls.
Time frame: 6 months